When someone injects insulin under the skin, the drug does not rush straight into the bloodstream. Insulin molecules have a strong tendency to cluster together into groups of six, called hexamers. The body has to disassemble those clusters before it can absorb and use the insulin. That delay, measured in tens of minutes, is one of the core engineering challenges in diabetes management.
A recent abstract published in Advanced Materials describes a materials-based approach to that problem. Researchers worked with a monomeric insulin analog called HALQ, meaning it is designed to stay as single molecules rather than forming hexamers, and paired it with a novel stabilizing excipient derived from inulin. The combination produced an insulin formulation that, in a porcine diabetes model and in pharmacokinetic simulations, absorbed faster and cleared the body sooner than existing ultrarapid insulin formulations.
The study is preclinical, and no human trials are reported. Still, the findings offer a window into how peptide chemistry and material science are being combined to rethink the speed limits of insulin therapy.
The hexamer problem
Insulin is a peptide hormone, a short chain of amino acids that tells cells to take up glucose from the blood. In its natural and most stable state, six insulin molecules bind together with zinc ions to form a hexamer. This hexameric structure is chemically stable, which makes it useful for manufacturing and storage. The problem is that hexamers are too large to cross capillary walls. Before insulin can act, the hexamers must first break apart into dimers, then into individual monomers.
That disassembly process takes time. Rapid-acting insulin formulations approved for clinical use have been engineered with amino acid substitutions that weaken the tendency to form hexamers, speeding up that process. But even the fastest of these still peak in the bloodstream around 60 minutes after injection in modeling that accounts for human physiology, according to the published abstract.
Monomeric analogs like HALQ take a more direct approach: they are designed so that the molecules largely stay separate from the start. The absorption barrier is reduced because there is less clustering to undo. The challenge then shifts to stability, since monomers are more prone to aggregation and chemical degradation over time.
The stabilizing excipient
An excipient is any inactive ingredient added to a drug formulation to support the active compound. It might adjust pH, prevent degradation, or, in this case, protect the monomeric structure of HALQ without interfering with its biological activity.
The researchers developed a compound called BN-Inu, derived from inulin, which is a naturally occurring plant fiber. The abstract describes BN-Inu as a non-interacting excipient, meaning it stabilizes HALQ without binding to it or altering its structure in ways that would change how it behaves in the body.
In stability testing, the HALQ-plus-BN-Inu formulation maintained integrity for 96 hours under stress conditions and for at least 30 days at room temperature. Room-temperature stability is a practical concern in real-world use, since insulin that must be kept refrigerated continuously presents logistical challenges in many settings.
Animal model results
The researchers tested HALQ in a porcine, or pig, model of diabetes. Pigs are commonly used in pharmacokinetic studies because their subcutaneous tissue and insulin physiology share meaningful similarities with humans.
In that model, HALQ showed significantly faster absorption and a shorter duration of action than one existing ultrarapid insulin formulation used as a comparator. The abstract describes this as a fast-on, fast-off profile, meaning the drug rose quickly in the bloodstream and also cleared more quickly than the comparator.
The researchers then added clinically used absorption enhancers to the HALQ formulation. These are compounds that have already been studied in other contexts for their ability to speed movement of drugs across tissue. With those enhancers included, the formulation showed an even faster time-to-peak and a reduced overall exposure in the bloodstream compared to a second ultrarapid comparator in the animal model.
Human physiology modeling
Animal pharmacokinetics do not translate directly to humans, so the team used pharmacokinetic modeling to estimate what HALQ's profile might look like in human physiology. Pharmacokinetic modeling uses mathematical equations built from known biological parameters to simulate how a drug would be absorbed, distributed, and cleared in a different species or condition.
The simulations predicted that HALQ could reduce time-to-peak insulin concentration in humans from approximately 60 minutes to 39 minutes. They also predicted that the duration of action could shorten from roughly 143 minutes to 84 minutes.
These are model predictions, not clinical measurements. The abstract is explicit that translation to human physiology was evaluated through simulation. Simulation-based predictions require validation in human clinical trials before any conclusions about real-world performance can be drawn. That said, the modeling methodology is a standard tool used to guide decisions about whether a compound is worth advancing toward those trials.
Why faster clearance matters in research terms
The abstract frames the fast-off aspect of HALQ's profile as being more consistent with endogenous prandial insulin physiology. Prandial means related to meals. In people without diabetes, the pancreas releases a burst of insulin in direct response to rising blood glucose after eating, and that insulin clears relatively quickly once glucose levels normalize.
Existing rapid-acting formulations, even the fastest ones, have a duration of action that extends well beyond the typical postmeal glucose rise. Researchers studying this mismatch have long hypothesized that a more tightly timed profile could, in principle, reduce the risk of late hypoglycemia, meaning low blood sugar that occurs hours after a meal when injected insulin is still active but the meal-driven glucose has already returned to baseline.
The study does not measure hypoglycemia outcomes. It measures pharmacokinetics, meaning the time course of insulin concentration in the blood. The connection between a faster pharmacokinetic profile and clinical outcomes remains a hypothesis to be tested in humans.
Broader context in peptide formulation science
This research sits at an intersection of peptide chemistry and materials science. Designing an analog with the right amino acid sequence is one part of the challenge. Keeping that analog stable long enough to be manufactured, stored, shipped, and used is another part entirely.
The inulin-derived excipient approach described here is notable because it decouples the stability problem from the activity of the peptide itself. Rather than modifying the insulin molecule further to make it more stable, which can alter its pharmacology, the researchers developed an external compound to do the stabilizing work. That strategy, if it generalizes, could be applicable to other peptide analogs where monomer form is desirable but stability is difficult to maintain.
The abstract concludes that monomer-stabilizing excipients enable next-generation ultrafast insulin formulations. The authors describe the findings as demonstrating potential utility rather than proven clinical benefit. That careful framing reflects where the science currently stands: compelling preclinical data and predictive modeling, with the harder work of human trials still ahead.
